Interestingly, the combination of afatinib and cetuximab, an EGFR-specific antibody, treatment resulted in extensive tumor shrinkage of erlotinib-resistant tumors harboring the T790M mutation in mice but either agent alone was much less effective [47]. Here, EGFR is linked to neoplasm.